CMPX (Compass Therapeutics) Common Stock: $0.02 Mil (As of Mar. 2026)


CMPX Compass Therapeutics Inc CMPX
23 GF Score
Price $2.34
! 2 Warning Signs
View Full Analysis

What is Compass Therapeutics Common Stock?

Compass Therapeutics CMPX +0.86% 23 Common Stock is $0.02 Mil as of Mar. 2026. GuruFocus rates CMPX with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

Compass Therapeutics's quarterly common stock declined from Sep. 2025 ($0.05 Mil) to Dec. 2025 ($0.02 Mil) but then stayed the same from Dec. 2025 ($0.02 Mil) to Mar. 2026 ($0.02 Mil).

Compass Therapeutics's annual common stock increased from Dec. 2023 ($0.01 Mil) to Dec. 2024 ($0.01 Mil) and increased from Dec. 2024 ($0.01 Mil) to Dec. 2025 ($0.02 Mil).

Compass Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for Compass Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Compass Therapeutics Common Stock Chart

Compass Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial 0.01 0.01 0.01 0.01 0.02

Compass Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.05 0.02 0.02
CMPX
23GF Score
Compass Therapeutics Inc CMPX
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Compass Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.02 Mil mean?
Compass Therapeutics (CMPX) has a Common Stock of $0.02 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Compass Therapeutics and its competitors.
Is Compass Therapeutics' Common Stock too high?
Compass Therapeutics' current Common Stock is $0.02 Mil. Overall, Compass Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Compass Therapeutics' Common Stock compare to XFOR and LRMR?
Compass Therapeutics' Common Stock of $0.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Compass Therapeutics and its competitors. Compass Therapeutics's current Common Stock is $0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compass Therapeutics stock overvalued right now?
Compass Therapeutics (CMPX) has a current Common Stock of $0.02 Mil. The current Common Stock is $0.02 Mil. Compass Therapeutics' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Compass Therapeutics (CMPX), the current Common Stock is $0.02 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Compass Therapeutics Business Description

Address 80 Guest Street, Suite 601, Boston, MA, USA, 02135
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
23GF Score

Get the complete analysis for CMPX

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.34
Price